Sansheng Pharmaceutical's long-acting erythropoietin SSS06 project phase III clinical trial completed the first subject enrollment

SHENYANG, March 16, 2022 /PRNewswire/ -- Today, 3SBio announced that the recombinant erythropoiesis-stimulating protein injection (rESP, CHO cell) (drug code: SSS06), developed by 3SBio, is currently under "Comparing the efficacy and safety of intravenous recombinant erythropoiesis-stimulating protein injection (CHO cells) and EPIAO in the maintenance treatment of chronic renal failure anemia patients on hemodialysis: a multicenter, randomized, parallel controlled phase III clinical trial ”, the first subject has been enrolled in the group recently, and the first dose has been successfully completed according to the protocol

In the previously completed Phase I and Phase II studies, clinical data show that SSS06 is safe and well tolerated, the drug has a longer half-life and stability, and no anti-drug antibody (ADA) production was detected, which can significantly Reduce the frequency of medication and provide more convenient treatment for patients

Clinical data in recent years have shown that due to the short half-life of rHuEPO and the frequent administration of rHuEPO, it brings inconvenience to patients and medical staff

Anemia is a common complication of chronic kidney disease (CKD), and the incidence of anemia gradually increases with the decline of renal function.

Anemia often occurs in the early stages of the development of chronic renal failure

Dr.

References: (1) Lin Pan Ding Xiaoqiang et al

Cautionary Note and Forward-Looking Statements

This press release contains forward-looking statements, such as those concerning business and product prospects, or the company's intentions, plans, perceptions, expectations and strategies

Source: 3SBio